Alan J. Green

Covalent targeted radioligands potentiate radionuclide therapy

[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study

MIRD Pamphlet No. 24: Guidelines for Quantitative ¹³¹I SPECT in Dosimetry Applications

MIRD Pamphlet No. 20: The Effect of Model Assumptions on Kidney Dosimetry and Response—Implications for Radionuclide Therapy